Impact of clonal TP53 mutations with loss of heterozygosity on adjuvant chemotherapy and immunotherapy in gastric cancer.
Yun GuMengyao SunHanji FangFei ShaoChao LinHao LiuHe LiHongyong HeRuochen LiJieti WangHeng ZhangJiejie XuPublished in: British journal of cancer (2024)
TP53 C-LOH GCs with genomic instability and immune evasion phenotype have poor clinical outcomes in patients treated with ACT or immunotherapy.
Keyphrases